Double-Masked, Randomized, Placebo-Controlled Clinical Study of the Mast Cell-Stabilizing Effects of Treatment with Olopatadine in the Conjunctival Allergen Challenge Model in Humans

Clinical Therapeutics

Volumn 25, Issue 10, 2003, Pages 2539-2552

  Leonardi, Andrea ^a   Abelson, Mark B ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b Ophthalmic Research Associates Inc   (United States)

Author keywords

Conjunctival allergen challenge; Histamine; Mast cell stabilizing allergic conjunctivitis; Olopatadine

Indexed keywords

ALLERGEN; ARTIFICIAL TEAR; HISTAMINE; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; OLOPATADINE; PLACEBO;

ADULT; ALLERGIC CONJUNCTIVITIS; ARTICLE; CELL COUNT; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVA EPITHELIUM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EOSINOPHIL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMPRESSION CYTOLOGY; INFLAMMATORY CELL; LYMPHOCYTE; MALE; MAST CELL; NEUTROPHIL; OCULAR PRURITUS; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL;

EID: 0242677574     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80315-6     Document Type: Article

References (33)

1. Bielory L. Update on ocular allergy treatment. Expert Opin Pharmacother. 2002;3: 541-553.
2. Abelson MB, Schaefer K. Conjunctivitis of allergic origin: Immunologic mechanisms and current approaches to therapy. Surv Ophthalmol. 1993;38(Suppl):115-132.
3. Abelson MB, Chapin MJ. Current and future topical treatments for ocular allergy. Compre Ophthalmol Update. 2000;1:303-320.
4. Abelson MB, Pyun J. Histamine. In: Abelson MB, ed. Allergic Diseases of the Eye. Philadelphia, Pa: WB Saunders; 2001:63-74.
5. Church MK, Holgate ST, Shute JK, et al. Mast cell derived mediators. In: Middleton E, Reed CE, Ellis ET, et al, eds. Allergy. Principles and Practice. St. Louis, Mo: Mosby; 1988:146-167.
6. Ciprandi G, Buscaglia S, Pesce G, et al. Allergic subjects express intercellular adhesion molecule-1 (ICAM-1 or CD54) on epithelial cells of conjunctiva after allergen challenge. J Allergy Clin Immunol 1993;91:783-792.
7. Bacon AS, McGill JI, Anderson DF, et al. Adhesion molecules and relationship to leukocyte levels in allergic eye disease. Invest Ophthalmol Vis Sci. 1998;39:330-332.
8. Collum LMT, Kilmartin DJ. Acute allergic conjunctivitis. In: Abelson MB, ed. Allergic Diseases of the Eye. Philadelphia, Pa: WB Saunders; 2001:112-136.
9. Spangler DL, Bensch G, Berdy GJ. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model. Clin Ther 2001;23:1272-1280.
10. Udell IJ, Kenyon KR, Hanninen LA, Abelson MB. Time course of human conjunctival mast cell degranulation in response to compound 48/80. Acta Ophthalmol Suppl. 1987;192:154-161.
11. Anderson DF, Macleod JD, Baddeley SM, et al. Seasonal allergic conjunctivitis is accompanied by increased mast cell numbers in the absence of leucocyte infiltration. Clin Exp Allergy. 1997;27:1060-1066.
12. Abelson MB, Madiwale N, Weston JH. Conjunctival eosinophils in allergic ocular disease. Arch Ophthalmol. 1983;101:555-556.
13. Bonini S, Bonini S, Vecchione A, et al. Inflammatory changes in conjunctival scrapings after allergen provocation in humans. J Allergy Clin Immunol. 1988;82:462-469.
14. Casey R. Atopic conjunctivitis. In: Abelson MB, ed. Allergic Diseases of the Eye. Philadelphia, Pa: WB Saunders; 2001;137-143.
15. Leonardi A, Smith LM, Secchi AG. Vernal keratoconjunctivitis. In: Abelson MB, ed. Allergic Diseases of the Eye. Philadelphia, Pa: WB Saunders; 2001;183-200.
16. Yanni JM, Miller ST, Gamache DA, et al. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann Allergy Asthma Immunol. 1997;79:541-545.
17. Schoch C. In vitro inhibition of human conjunctival mast-cell degranulation by ketotifen. J Ocul Pharmacol Ther. 2003;19:75-81.
18. Chand N, Pillar J, Diamantis W, Sofia RD. Inhibition of IgE-mediated allergic histamine release from rat peritoneal mast cells by azelastine and selected antiallergic drugs. Agents Actions. 1985;16:318-322.
19. Lytinas M, Kempuraj D, Huang M, et al. Azelastine's inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: Comparison with olopatadine. Allergy Asthma Proc. 2002;23:45-51.
20. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol. 1990;108:84-88.
21. Bonini S, Bonini S, Bucci MG, et al. Allergen dose response and late symptoms in a human model of ocular allergy. J Allergy Clin Immunol. 1990;86:869-876.
22. Leonardi A, Smith LM, Fregona IA, et al. Tear histamine and histaminase during the early (EPR) and late (LPR) phases of the allergic reaction and the effects of lodoxamide. Eur J Ophthalmol. 1996;6:106-112.
23. 2003 PDR for Ophthalmic Medicines. Montvale, NJ: Thomson PDR; 2003.
24. Leonardi A, Papa V, Milazzo G, Secchi AG. Efficacy and safety of desonide phosphate for the treatment of allergic conjunctivitis. Cornea. 2002;21:476-481.
25. Sharif NA, Xu SX, Miller ST, et al. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther. 1996;278:1252-1261.
26. Miyake K, Horikoshi K, Ikeda Y, et al. Effects of olopatadine hydrochloride on the increase of histamine and peptide-leukotrienes concentrations in nasal lavage fluid following the antigen-antibody reaction in actively sensitized guinea pigs. Jpn J Pharmacol. 2001;85:453-456.
27. Anderson DF, Zhang S, Bradding P, et al. The relative contribution of mast cell subsets to conjunctival TH2-like cytokines. Invest Ophthalmol Vis Sci. 2001;42:995-1001.
28. Cook EB, Stahl JL, Miller ST, et al. Isolation of human conjunctival mast cells and epithelial cells: Tumor necrosis factor-alpha from mast cells affects intercellular adhesion molecule 1 expression on epithelial cells. Invest Ophthalmol Vis Sci. 1998;39:336-343.
29. Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits TNF-alpha release from human conjunctival mast cells. Ann Allergy Asthma Immunol. 2000;84:504-508.
30. Irkec M, Bozkurt B, Kerimoglu H, et al. Topical olopatadine decreases tear eotaxin in patients with seasonal allergic conjunctivitis (SAC). Poster presented at: Annual Meeting of the Association for Research in Vision and Ophthalmology; April 29-May 4, 2001; Fort Lauderdale, Fla.
31. 2-receptors in the human ocular surface. Arch Ophthalmol. 1981;99:302-304.
32. 2-receptors in cutaneous inflammation in the guinea-pig produced by histamine and mast cell degranulation. Br J Pharmacol. 1980;69:615-623.
33. Abelson MB, Gomes PG, Schultz C. Cytokines in the ocular environment. In: Abelson MB, ed. Allergic Diseases of the Eye. Philadelphia, Pa: WB Saunders; 2001:83-90.